Skip to main content
An official website of the United States government
Email

NIH study finds two doses of HPV vaccine may be as protective as full course

, by DCEG Staff

Two doses of the human papillomavirus (HPV) vaccine Cervarix were as effective as the current standard three-dose regimen after four years of follow-up, according to researchers from the National Cancer Institute (NCI), part of the National Institutes of Health, and their colleagues. The results of the study, based on data from a community-based clinical trial of Cervarix in Costa Rica, appeared online Sept 9, 2011, in the Journal of the National Cancer Institute.

NCI Cancer Bulletin (Archive): HPV vaccine study in Costa Rica yields insights on cancer prevention

News article in the NCI newsletter the Cancer Bulletin (Archive)

 

< Older Post

Cigarette smoking implicated in half of bladder cancers in women

Newer Post >

Women exposed to DES in the womb face increased cancer risk

Email